Latest Nhs News

Alcidion Group Limited has delivered a record FY25 with $40.8 million in revenue and underlying EBITDA of $5.1 million, driven by a landmark $39 million UK electronic patient record contract and strong recurring revenue growth.

Alcidion Group Limited has reported a transformative FY25 with record earnings, a major NHS contract win, and a robust outlook for FY26. The company’s healthcare technology platform is gaining traction across the UK and Australia, setting the stage for accelerated growth.

Genetic Signatures reported a 63% revenue increase to $15.9 million in FY25, alongside a 28% reduction in underlying losses and a strategic shift in its automated diagnostics platform development.

Genetic Signatures Limited reported a 63% revenue surge to $15.9 million in FY25, driven by strong Australian sales and progress in EMEA, while navigating a $20.1 million net loss and a strategic pivot towards partnerships for automated diagnostics.

Sonic Healthcare delivered solid FY2025 results with 8% revenue growth and a 7% rise in net profit, setting the stage for an anticipated 19% earnings per share increase in FY2026.

Sonic Healthcare reported solid FY2025 results with revenue up 7.6% and a steady profit increase, while declaring a 63-cent final dividend. The company’s recent German acquisition and ongoing synergy efforts set the stage for robust earnings growth in FY2026.

Control Bionics capped a record FY25 with 15% revenue growth, driven by US market gains and expanding NeuroNode and NeuroStrip technologies. The company also achieved a US profitability milestone and is close to finalizing key distribution partnerships.

Alcidion Group Limited has reported its strongest quarter ever with record operating cashflow and a doubling of new sales, reaffirming its positive outlook for FY25.

HITIQ Limited is set to debut its PROTEQT concussion management system in the UK on August 4, 2025, uniquely integrating with NHS 111 telehealth services to offer free medical guidance. This launch marks HITIQ’s first international consumer market entry and a strategic step in its global expansion.

Beamtree Holdings has forged a strategic alliance with the NHS Confederation to launch a pioneering healthcare analytics platform across UK NHS Trusts, marking a significant step in its international expansion.

Beamtree Holdings has landed a landmark NHS contract and multiple international deals, positioning itself for robust annual recurring revenue growth and improved profitability by the end of FY25.

Control Bionics reports its strongest US revenue in years alongside Australia’s best quarter since 2022, propelled by new product launches and strategic investments.